Immunovant Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
12.2%projected annual EPS growth
Analyst Coverage
16analysts covering
FY EPS (est.)
-$2.92next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly902.1MTarget: Sufficient to fund operations through potential commercial launch of IMVT-1402 in Graves' disease
Annual Research and Development (R&D) Expenses Annually456.7MTarget: Optimized allocation following batoclimab discontinuation
Watch Items
- IMVT-1402 Cutaneous Lupus Erythematosus (CLE) Proof-of-Concept TrialTrigger: Topline data readout expected in H2 2026Action: Evaluate efficacy and safety profile to determine registrational path
- IMVT-1402 Registrational Trials in Graves' Disease (GD) and Myasthenia Gravis (MG)Trigger: Topline data readouts expected in calendar year 2027Action: Monitor enrollment progress and prepare regulatory filing strategies
Research as of 19 Jun 2026